8-KShareholder Matters

AbbVie Inc. 8-K Report, Shareholder Vote Results (May 8, 2018)

Filed May 8, 2018For Securities:ABBV

Summary

This 8-K filing from AbbVie Inc., dated May 8, 2018, reports on the outcomes of its Annual Meeting of Stockholders held on May 4, 2018. The key takeaways for investors revolve around the strong support for the re-election of directors and the ratification of the independent auditor, signaling continued confidence in the company's leadership and financial oversight. Investor sentiment was also reflected in the advisory vote on executive compensation and the approved frequency of such votes, indicating general satisfaction with the company's pay practices. However, the filing also highlights areas where stockholder proposals did not gain majority support, including amendments to the certificate of incorporation related to director elections and eliminating supermajority voting, as well as specific stockholder-initiated proposals concerning lobbying reports, separation of Chair and CEO roles, and a compensation committee report on drug pricing. These results provide insight into shareholder priorities and potential areas of ongoing engagement for the company.

Key Highlights

  • 1All incumbent Class III Directors proposed for re-election were overwhelmingly approved by stockholders.
  • 2Ernst & Young LLP was ratified as AbbVie's independent registered public accounting firm for 2018 with substantial support.
  • 3Stockholders approved, on an advisory basis, the compensation of named executive officers and the frequency of say-on-pay votes, with '1 Year' being the preferred frequency.
  • 4A management proposal to amend the certificate of incorporation for annual director elections was not approved.
  • 5A management proposal to eliminate supermajority voting requirements in the certificate of incorporation was not approved.
  • 6Stockholder proposals requesting a lobbying report, separating the Chair and CEO roles, and issuing an annual Compensation Committee report on drug pricing all failed to gain majority approval.

Frequently Asked Questions

The primary outcomes include the re-election of all proposed Class III Directors, the ratification of Ernst & Young LLP as the independent auditor, and advisory approval of executive compensation and the frequency of say-on-pay votes. Several management and stockholder proposals did not receive majority approval.

Two management proposals related to amendments to the certificate of incorporation did not pass: one concerning the annual election of directors and another to eliminate supermajority voting. The advisory vote on executive compensation and the frequency of that vote were approved.

All three stockholder-initiated proposals – to issue a lobbying report, separate the Chair and CEO positions, and to issue an annual Compensation Committee report on drug pricing – failed to receive majority support from the stockholders.

The advisory vote, often referred to as 'say-on-pay,' indicated that a majority of the voting stockholders were in favor of the compensation paid to AbbVie's named executive officers. The preferred frequency for these advisory votes was overwhelmingly '1 Year'.